Express Pharma

Ajanta Pharma posts standalone and third quarter results


Board of Directors has approved sub-division of nominal value of equity shares of the company from Rs 5 each to nominal value of Rs 2 each

Ajanta Pharma reported its performance for the third quarter and nine months ended December 31, 2014. The revenue from operations grew 21 per cent at Rs 363 crore against Rs 301 crore in the third quarter. Earnings before interest, taxes, depreciation, and amortization (EBITDA) has grown 32 per cent at Rs 131 crore against Rs 99 crore. EBITDA was posted at 36 per cent of revenue. Profit before tax was at Rs 124 crore against Rs 90 crore, registering a growth of 38 per cent.

Profit after tax (PAT) grew 36 per cent at Rs 85 crore against Rs 62 crore. PAT at 23 per cent of revenue. Exports contributed 67 per cent of the revenue for the quarter.

In the nine months, standalone financial performan